Premium
Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant
Author(s) -
Hasegawa Hideki,
Ichinohe Takeshi,
Strong Peter,
Watanabe Izumi,
Ito Satoshi,
Tamura Shinichi,
Takahashi Hidehiro,
Sawa Hirofumi,
Chiba Joe,
Kurata Takeshi,
Sata Tetsutaro
Publication year - 2005
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.20247
Subject(s) - nasal administration , adjuvant , hemagglutinin (influenza) , vaccination , virology , virus , influenza vaccine , microbiology and biotechnology , influenza a virus , immunization , medicine , titer , immunology , immune system , biology
Chitin in the form of microparticles (chitin microparticles, CMP) has been demonstrated to be a potent stimulator of macrophages, promoting T‐helper‐1 (Th1) activation and cytokine response. In order to examine the mucosal adjuvant effect of CMP co‐administered with influenza hemagglutinin (HA) vaccine against influenza infection, CMP were intranasally co‐administered with influenza HA vaccine prepared from PR8 (H1N1) virus. Inoculation of the vaccine with CMP induced primary and secondary anti‐HA IgA responses in the nasal wash and anti‐HA IgG responses in the serum, which were significantly higher than those of nasal vaccination without CMP, and provided a complete protection against a homologous influenza virus challenge in the nasal infection influenza model. In addition, CMP‐based immunization using A/Yamagata (H1N1) and A/Guizhou (H3N2) induced PR8 HA‐reactive IgA in the nasal washes and specific‐IgG in the serum. The immunization with A/Yamagata and CMP resulted in complete protection against a PR8 (H1N1) challenge in A/Yamagata (H1N1)‐vaccinated mice, while that with A/Guizhou (H3N2) and CMP exhibited a 100‐fold reduction of nasal virus titer, demonstrating the cross‐protective effect of CMP and influenza vaccine. It is suggested that CMP provide a safe and effective adjuvant for nasal vaccination with inactivated influenza vaccine. J. Med. Virol. 75:130–136, 2005. © 2005 Wiley‐Liss, Inc.